Statin With Palliative Therapy for HCC

HCC Clinical Trial

Official title:

Statin With Palliative Therapy for HCC

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02785874
• Other study ID #: N201603038
• Status: Terminated
• Phase: N/A
• First received: May 25, 2016
• Last updated: April 18, 2017
• Start date: September 1, 2016
• Est. completion date: November 1, 2016

Study information

• Verified date: May 2016
• Source: Taipei Medical University WanFang Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer,however, the investigators also discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.

Description:

Most liver cancer patients did not accept the cure as the main objective of the treatment after diagnosis because they choose alternative therapies palliative based, such as hepatic arterial chemoembolization, chemotherapy and radiation therapy.

Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer, yet the clinical effect for Statin is still unknown.

In a previous study of 20,220 liver cancer patients in health care database, the investigators discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.

This study is a continuation of previous health insurance database studies for clinical trials to verify whether Statin could prolong disease-free survival role for palliative treatment of liver cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: November 1, 2016
• Est. primary completion date: October 1, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

1. >20 years old.

2. BCLC stage B , stage C and stage D

Exclusion Criteria:

1. Cancer diagnosis before HCC was con?rmed and incurable.

2. <20 years old, > 90years old.

3. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator

Related Conditions & MeSH terms

• HCC

Intervention

Drug:
• Statin
Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival

Locations

Country	Name	City	State
Taiwan	WanFangHospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University WanFang Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival		Up to two year